U.S Approves River Blindness Drug Co-Developed By Ugandan Doctor

Posted by: lukwago J in Health June 20, 2018

The Ugandan Doctor by the names of Nyathirombo Amos is in celebrations about the scientific journey of six years World Health Organisation led analysis of a more effective River Blindness drug he co-developed.

Check also: Here Are New Drugs And Therapies That Helps Us Live Longer

The U.S Food and Drug Administration organization declared last Saturday that it has approved the drug called Moxidectin 8mg Oral which treats River Blindness in patients of 12 years or more.

This was after a successful research by Dr Nyathirombo Amos including 18 other doctors from 4 different African countries who discovered that Moxidectin which was formerly a veterinary medicine was more successful in treating River Blindness even better than Ivermectin that was commonly used.

The discoveries were published in Lancet, a respected medical journal early this year. The research was financed by organizations like United Nations Development Program, Who Special Program for research, Training Tropical Diseases, World Bank and the United Nations Children’s Fund.

Personally, am very excited for my contribution towards the development of this medicine for mankind, ‘’said Dr Nyathirombo.

The Moxidectin drug was initially used as a veterinary medicine for de-worming domestic animals, but when we discovered that it could also help treat River Blindness, we decided to take it to the laboratory for further research.

The research which was carried out in Uganda, Liberia, DR Congo and Ghana compared the ability and effectiveness of both Moxidectin and Ivermectin and finally realized that Moxidectin killed the River Blindness worms in the skin and eyes faster in humans.

Check also;

This is not a Paywall, but Newslex Point's journalism consumes a lot of time, hard-work and money. That's why we're kindly requesting you to support us in anyway they can, for as little as $1 or more, you can support us .

Please use the button below to contribute to Newslex Point, Inc. using a credit card or via PayPal.